Status:
COMPLETED
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Psoriasis
Eligibility:
All Genders
18-100 years
Brief Summary
This non-interventional, prospective, multi-center study aims to provide short- and long- term treatment patterns, effectiveness, and safety of secukinumab in Chinese patients with moderate to severe ...
Detailed Description
All patients will be followed up for 52 weeks no matter they adhere to secukinumab or they have shifted to other treatment plans. Data will be collected in conjunction with routine care visits, most l...
Eligibility Criteria
Inclusion
- Aged ≥ 18 years;
- Diagnosis of clinically moderate to severe plaque-psoriasis;
- Initiating treatment with secukinumab during the identification period or within 30 days prior to the index date;
- Patient agrees to sign the informed consent
Exclusion
- \- Participation in any dermatology or rheumatology clinical trial, concurrent or within the last 30 days of the secukinumab initiating date
Key Trial Info
Start Date :
September 26 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
1002 Patients enrolled
Trial Details
Trial ID
NCT04894890
Start Date
September 26 2021
End Date
December 15 2023
Last Update
March 20 2024
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Xicheng Direct, Beijing Municipality, China, 100044
2
Novartis Investigative Site
Chongqing, Chongqing Municipality, China, 400010
3
Novartis Investigative Site
Lanzhou, Gansu, China, 730030
4
Novartis Investigative Site
Guangzhou, Guangdong, China, 510000